Abstract:Background: Lung cancer (LC) is still the most common cause of cancer related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all LC cases but is not a single entity. It is now accepted that, apart from the characteristic driver mutations, the unique molecular signatures of adeno- (AC) and squamous cell carcinomas (SCC), the two most common NSCLC subtypes should be taken into consideration for their management. Therapeutic interventions, however, frequently lead to chemotherapy resistance highlighting the need for in-depth analysis of regulatory mechanisms of multidrug resistance to increase therapeutic efficiency. Methods: Non-canonical Wnt5a and canonical Wnt7b and ABC transporter expressions were tested in primary human LC (n = 90) resections of AC and SCC. To investigate drug transporter activity, a three dimensional (3D) human lung aggregate tissue model was set up using differentiated primary human lung cell types. Following modification of the canonical, beta-catenin dependent Wnt pathway or treatment with cisplatin, drug transporter analysis was performed at mRNA, protein and functional level using qRT-PCR, immunohistochemistry, immune-fluorescent staining and transport function analysis. Results: Non-canonical Wnt5a is significantly up-regulated in SCC samples making the microenvironment different from AC, where the beta-catenin dependent Wnt7b is more prominent. In primary cancer tissues ABCB1 and ABCG2 expression levels were different in the two NSCLC subtypes. Non-canonical rhWnt5a induced down-regulation of both ABCB1 and ABCG2 transporters in the primary human lung aggregate tissue model recreating the SCC-like transporter pattern. Inhibition of the beta-catenin or canonical Wnt pathway resulted in similar down-regulation of both ABC transporter expression and function. In contrast, cisplatin, the frequently used adjuvant chemotherapeutic agent, activated beta-catenin dependent signaling that lead to up-regulation of both ABCB1 and ABCG2 transporter expression and activity. Conclusions: The difference in the Wnt microenvironment in AC and SCC leads to variations in ABC transporter expression. Cisplatin via induction of canonical Wnt signaling up-regulates ABCB1 and ABCG2 drug transporters that are not transporters for cisplatin itself but are transporters for drugs that are frequently used in combination therapy with cisplatin modulating drug response.

Expression of Abc Transporters is an Unfavorable Prognostic Factor in Laryngeal Squamous Cell Carcinoma

Expression And Significance Of Glucose Transporter-1, P-Glycoprotein, Multidrug Resistance-Associated Protein And Glutathione S-Transferase-Pi In Laryngeal Carcinoma

Expression and Function of ABCG2 in Head and Neck Squamous Cell Carcinoma and Cell Lines.

The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas

ABCG2 is Associated with HER-2 Expression, Lymph Node Metastasis and Clinical Stage in Breast Invasive Ductal Carcinoma

ABCG2 Regulated by MAPK Pathways is Associated with Cancer Progression in Laryngeal Squamous Cell Carcinoma.

Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer

Co-expression of ATP Binding Cassette Transporters is Associated with Poor Prognosis in Acute Myeloid Leukemia

[Expression of ATP-binding Cassette Transporter ABCG2 in Gastric Carcinoma and Its Significance].

Varied clinical significance of ATP-binding cassette C sub-family members for lung adenocarcinoma

The prognostic significance of ABCG1 for patients with Bladder cancer

Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma

ABCG2 Gene Expression in Non-Small Cell Lung Cancer

Comprehensive Analysis of ABCA Family Members in Lung Adenocarcinoma with Prognostic Values

ABCB1 Regulates Immune Genes in Breast Cancer

Effect of Apoptotic and Proliferative Indices, P-glycoprotein and Survivin Expression on Prognosis in Laryngeal Squamous Cell Carcinoma

Expressions and clinical significance of varied membrae transport proteins in patients with early non-small cell lung cancer

ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling

Expression of ABCG2 in Human Liver Cancer Cell Lines and Its Related Functions

Prognostic significance and molecular mechanisms of adenosine triphosphate-binding cassette subfamily C members in gastric cancer

Expressions of ABCG2 and CD44~+/CD24~- cells in breast carcinoma and their relationship with prognosis